Related Experiment Video
Updated: Aug 9, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
[Radiation doses from patients undergoing yttrium-90 silicate knee radiosynovectomy]
Kosmas Badiavas1, Dimitrios Chatzopoulos, Pavlos Markou
19 Melenikou Str., 582 00 Edessa, Macedonia, Greece.
Hellenic Journal of Nuclear Medicine
|April 18, 2006
Summary
Minimal radiation doses from Yttrium-90 silicate colloid (90Y-SC) for knee radiosynovectomy are well below safety limits. This study quantines radiation exposure for patients and staff, finding it safe for public and professional contact.
Area of Science:
- Nuclear Medicine
- Radiopharmacology
- Radiation Safety
Context:
- Radiosynovectomy (RS) is a treatment for knee synovitis.
- Limited data exists on radiation doses from Yttrium-90 silicate colloid (90Y-SC) in RS.
- Assessing radiation exposure is crucial for patient and staff safety.
Purpose:
- To measure and estimate radiation doses emitted by patients undergoing (90)Y-SC radiosynovectomy.
- To compare these doses with those from alternative radiopharmaceuticals.
- To ensure radiation exposure remains within regulatory limits.
Summary:
- Radiation dose rates were measured in 16 patients post-(90)Y-SC injection at varying distances.
- Mean dose rates were 0.6 microSv/h at 0.5m, decreasing with distance.
- Whole body doses for household members, nursing staff, and physicians were estimated and found to be significantly low.
Impact:
- The study establishes that (90)Y-SC knee synovectomy results in radiation doses well below annual limits for the public and professionals.
- Findings support the safety profile of (90)Y-SC compared to other radiopharmaceuticals for knee RS.
- Provides essential data for radiation safety protocols in nuclear medicine procedures.
